| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Axogen, Inc.$40.58
-3.03 (-6.95%)
D 27Pipeline Score MedTech · Clinical
Market Cap
2.10 B
EPS
-0.63
P/E Ratio
-62.43 $
Value Trade
23.05 M
SEC Financials
Q1 2026Dilution Risk
Revenue
61.46 M
R&D Expenses
7.52 M
Operating CF
1.56 M
Total Assets
289.49 M
Total Liabilities
44.68 M
Equity
244.81 M
D/E Ratio
12,345
0.39 %
Week
12.12 %
1 Month
16.26 %
3 Month
60.02 %
6 Month
92.56 %
5 Year
923.72 %
All Time
Cash Data
Cash Position
101.60 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 28, 2026
Overview
Volume
2.14 M
52 Week Range
9.22 - 45.83
% held by Insiders
2.91 %
% held by Institutions
92.18 %
Enterprise Value
2.02 B
Total Shares
46.10 M
Short %
7.1 %
Float Shares
43.47 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D27
Pipeline Score $186M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 29%
Small Cap (rank 648 of 911)
Percentile RankAxogen, Inc. faces pipeline headwinds (27/100), with $286M risk-adjusted pipeline value, led by Processed Nerve Allograft in Peripheral Nerve Discontinuities (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Processed Nerve Allograft Monoclonal antibody | Peripheral Nerve Discontinuities | Phase 3 | NCT01809002 | 57% | $286M | COMPLETED | 220 | - | - | Aug 30, 2021 | - | Jul 12, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Axoguard Nerve Cap | symptomatic neuroma | — | 2024-01-18 | The REPOSE clinical trial demonstrated that the Axoguard Nerve Cap significantly reduced total pain compared to standard neurectomy, achieving statistical superiority with a p-value <0.05 at the 12-month follow-up. Read More | Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap Read More | |
Axoguard Nerve Cap | symptomatic neuroma | — | 2024-01-18 | The REPOSE clinical trial demonstrated that the Axoguard Nerve Cap significantly reduced total pain compared to standard neurectomy, achieving statistical superiority with a p-value <0.05 at the 12-month follow-up. Read More | Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap Read More | |
Axoguard Nerve Cap | symptomatic neuroma | — | 2024-01-18 | The REPOSE clinical trial demonstrated that the Axoguard Nerve Cap significantly reduced total pain compared to standard neurectomy, achieving statistical superiority with a p-value <0.05 at the 12-month follow-up. Read More | Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AXGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AXGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AXGNAxogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
Axogen, Inc. will participate in the 2026 Bank of America Global Healthcare Conference, with management scheduled to present on May 13, 2026. The event will be accessible via a live audio webcast on the company's website. Axogen is focused on innovative surgical solutions for peripheral nerve function restoration.
Read more →AXGN▲ +6.6%on this newsshared move
Axogen, Inc. Reports First Quarter 2026 Financial Results
Axogen, Inc. reported a strong financial performance for Q1 2026, with revenues reaching $61.5 million, a 26.6% increase from the previous year. The company also saw improvements in gross margin and adjusted net income. However, it faced a net loss of $19.6 million, highlighting ongoing challenges in profitability. The firm remains optimistic about its growth trajectory and strategic objectives for the year.
Read more →AXGNAxogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
Axogen, Inc. has announced it will release its financial results for the first quarter of 2026 on April 28, 2026. Following the release, the management will host a conference call and webcast for investors. The company focuses on developing technologies for peripheral nerve repair and aims to set a standard of care in this field.
Read more →AXGN▼ -8.1%on this news
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
Axogen, Inc. reported strong financial results for Q4 and full-year 2025, highlighting significant achievements including FDA approval for Avance®, the only implantable biologic for peripheral nerve treatment. The company anticipates at least 18% revenue growth for 2026, reflecting confidence in its strategic plan and market development strategies. Axogen aims to make peripheral nerve restoration a standard of care.
Read more →AXGNAxogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen, Inc. has announced its participation in three upcoming investor conferences, including the Raymond James 47th Annual Institutional Investors Conference, the Leerink Global Healthcare Conference, and the Citizens Life Sciences Conference. These events will feature presentations and fireside chats, allowing management to engage with investors. Webcast links for the events are provided for live access and replays.
Read more →AXGNAxogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Axogen, Inc. has announced that it will release its financial results for the fourth quarter and full year 2025 on February 24, 2026. Following the release, the company will host a conference call and webcast for investors. Axogen is recognized for its innovative surgical solutions aimed at restoring peripheral nerve function.
Read more →AXGNAxogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
Axogen, Inc. has announced the pricing of an upsized public offering of 4 million shares at $31.00 each, aiming to raise approximately $124 million. The offering is set to close on January 23, 2026, and proceeds will be utilized for debt repayment and general corporate purposes. The offering is managed by Wells Fargo Securities and Mizuho, among others.
Read more →AXGNAxogen Announces Proposed Public Offering of Common Stock
Axogen, Inc. has announced a proposed public offering of $85 million in common stock, with an additional option for underwriters to purchase up to $12.75 million more. The funds will be used for debt repayment, working capital, and general corporate purposes. The offering is subject to market conditions and regulatory approval.
Read more →AXGN▼ -5.8%on this news
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 ALACHUA and TAMPA, FL
Axogen, Inc. has announced preliminary unaudited revenue figures for the fourth quarter and full year of 2025. The company expects Q4 revenue to reach approximately $59.9 million, representing a 21.3% increase over the same quarter in 2024. Full-year revenue is projected to be around $225.2 million, marking a 20.2% increase over 2024 figures. The FDA's approval of the Avance product is a significant milestone that bolsters Axogen's market strategy and operational execution.
Read more →AXGN▲ +7%on this news
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
Axogen, Inc. will participate in the J.P. Morgan 2026 Healthcare Conference, scheduled for January 15, 2026. The company's management will present at 10:30 AM PST, and a live audio webcast will be available. Axogen focuses on innovative surgical solutions for peripheral nerve repair and has a diverse product portfolio.
Read more →AXGNAxogen Announces FDA Approval of Biologics License Application for AVANCE (acellular nerve allograft-arwx) ALACHUA, FL and TAMPA, FL
Axogen, Inc. announced FDA approval of its Biologics License Application for AVANCE, an acellular nerve allograft intended for treating peripheral nerve discontinuities in patients aged 1 month or older. The approval comes under the Accelerated Approval pathway, based on evidence suggesting likely clinical benefits. The transition to a biologic classification is seen as a pivotal moment for Axogen, expected to enhance regulatory standing and market acceptance. However, further confirmatory trials are required to maintain this approval, raising potential risks.
Read more →AXGN▲ +23.1%on this news
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Axogen, Inc. reported a 23.5% increase in revenue for Q3 2025, totaling $60.1 million, with an adjusted EBITDA of $9.2 million. The company raised its full-year revenue guidance to at least $222.8 million, reflecting strong market growth and recognition of nerve allografts in clinical practice. However, they anticipate a minor impact on gross margin due to one-time costs associated with their upcoming BLA approval.
Read more →AXGNAxogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
Axogen, Inc. (NASDAQ: AXGN) announced it will report its financial results for the third quarter of 2025 on October 29, 2025, prior to market opening. The announcement includes an investment-community conference call scheduled for the same day at 8 a.m. ET. Axogen specializes in surgical solutions for peripheral nerve regeneration and offers a range of products designed to restore nerve function and improve quality of life for patients with nerve damage. Their product portfolio is marketed in multiple countries, showcasing their international presence.
Read more →AXGN▼ -9%on this newsshared move
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
Axogen, Inc. announced that the FDA has extended the PDUFA goal date for its Avance Nerve Graft BLA by three months to December 5, 2025. This extension follows a Major Amendment designation due to new manufacturing data submitted by the company. The FDA is expected to provide feedback on product labeling in November 2025, and the CEO expressed optimism about the ongoing engagement with the agency.
Read more →AXGN▼ -9%on this newsshared move
Axogen, Inc. Provides Update on FDA Review Timeline for Avance Nerve Graft FDA PDUFA Goal Date Extended by Three Months ALACHUA, FL and TAMPA, FL
Axogen, Inc. announced that the FDA has extended the PDUFA goal date for its Avance Nerve Graft by three months to December 5, 2025, due to a Major Amendment in its Biologics License Application. This amendment included substantial new manufacturing and facility data. The company expects to receive feedback on product labeling in November 2025. While the extension allows for thorough review, it may also indicate potential concerns requiring resolution before approval.
Read more →AXGN▲ +9.3%on this news
Axogen, Inc. Reports Second Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 17% Growth or $219 Million ALACHUA and TAMPA, FL
Axogen, Inc. reported strong financial results for the second quarter of 2025, with revenue up 18.3% year-over-year, reaching $56.7 million. The net income turned positive at $0.6 million, compared to a loss in the same quarter last year, prompting the company to raise its full-year revenue guidance to a minimum of 17% growth. Key business highlights include expanded insurance coverage for nerve repair solutions and regulatory milestones achieved concerning their Biologics License Application for Avance Nerve Graft, anticipated for approval in September 2025. Despite some potential impacts on gross margins from one-time costs associated with this approval, the company expresses confidence in its strategic growth objectives.
Read more →AXGNAxogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
Axogen, Inc. announced its participation in the Canaccord Genuity 45th Annual Growth Conference, scheduled for August 12, 2025. The company focuses on developing surgical solutions for peripheral nerve function restoration. Axogen's innovative products address various applications, including traumatic injuries and surgical procedures, enhancing patient quality of life.
Read more →AXGN▲ +8%on this news
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
Axogen, Inc. announced it will report its second quarter financial results for 2025 on August 5, 2025, prior to the market opening. Following this release, the company's management will host a conference call and webcast for the investment community at 8 a.m. ET. The announcement reflects Axogen's commitment to keeping investors informed about its financial performance. The company is renowned for its innovative surgical solutions in peripheral nerve regeneration and repair.
Read more →AXGNAxogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
Axogen, Inc. will participate in the Goldman Sachs Global Healthcare Conference on June 11, 2025. CEO Michael Dale will lead a fireside chat, providing insights into the company's innovative surgical solutions for peripheral nerve injuries. The event will be accessible via a live webcast, with replays available for 90 days.
Read more →AXGN▼ -23.2%on this news· ran to -34% by day 3
AXOGEN, INC. Condensed Consolidated Statements of Cash Flows (unaudited) Three Months Ended
Axogen, Inc. reported its first quarter financial results for 2025, showcasing a 17.4% revenue increase year-over-year. The gross margin saw a decline to 71.9% attributed to rising product costs. While the company experienced a net loss of $3.8 million, this was an improvement from the $6.6 million loss reported in the same quarter of 2024. Axogen also confirmed successful regulatory milestones as it prepares for the anticipated FDA approval of its Biologics License Application for the Avance Nerve Graft in September 2025.
Read more →AXGN▼ -23.2%on this news· ran to -34% by day 3
Axogen, Inc. Reports 2025 First Quarter Financial Results
Axogen, Inc. reported financial results for the first quarter of 2025, showing a 17.4% increase in revenue to $48.6 million compared to the previous year. The gross margin decreased to 71.9%, primarily due to higher product costs. The company registered a net loss of $3.8 million but improved its adjusted net loss to $0.9 million. Significant milestones included the acceptance of the Biologics License Application for Avance® Nerve Graft, with an anticipated approval date set for September 5, 2025.
Read more →AXGN▼ -23.2%on this news· ran to -34% by day 3
Axogen Announces Chief Financial Officer Transition
Axogen, Inc. has announced the appointment of Lindsey Hartley as Chief Financial Officer, effective May 12, 2025. Hartley, who has served as Vice President and Corporate Controller at Axogen, will succeed Nir Naor, who is leaving to pursue other opportunities. Naor will assist in the transition until July 1, 2025. Hartley brings over 19 years of financial leadership experience in the healthcare and medical device sectors, which is expected to aid Axogen's strategic growth and financial discipline moving forward.
Read more →AXGNAxogen, Inc. to report 2025 first quarter financial results on May 8, 2025
Axogen, Inc. has announced it will report its first quarter financial results for 2025 on May 8, 2025, prior to market opening. The company's management will conduct a conference call and webcast at 8 a.m. ET to discuss the results. This announcement highlights Axogen's continued commitment to providing innovative solutions for peripheral nerve injuries and enhances its visibility among investors.
Read more →AXGNAxogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Axogen, Inc. has appointed Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, effective March 24, 2025. He will develop strategies to support the standardization of peripheral nerve function restoration as a healthcare practice. Ditto's experience in the medical device sector, including significant roles at notable companies, is seen as a critical asset for Axogen. Additionally, as part of his employment agreement, Ditto will receive an inducement equity grant consisting of 45,000 shares of Axogen common stock, vesting over four years.
Read more →AXGN▲ +11.7%on this news
Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. reported positive financial results for Q4 and the full year 2024, with revenues growing by 15.1% in the fourth quarter and an adjusted net income of $5.9 million for the year. The company noted a strong revenue increase across its portfolio, attributed to improved commercial execution. Axogen's Biologics License Application for Avance® Nerve Graft was accepted by the FDA, with a PDUFA goal date set for September 2025. The company plans to discuss future strategies at an upcoming Investor Day event on March 4, 2025.
Read more →AXGN▲ +11.7%on this news
Axogen, Inc. To Host Analyst & Investor Day on March 4th
Axogen, Inc. will hold its Analyst & Investor Day on March 4, 2025, from 9 AM to 12 PM Eastern. Key executives, including the CEO and CFO, will present the company's overview, strategic initiatives, and financial results. The event aims to enhance investor understanding of Axogen's business and growth plans. A live webcast will be available for those unable to attend in person.
Read more →AXGNAxogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
Axogen, Inc. has announced that it will report its financial results for the fourth quarter and full year of 2024 on February 25, 2025, prior to market opening. Following the report, a conference call will be held for the investment community, providing insights into the company's performance. Axogen focuses on innovative surgical solutions for peripheral nerve injuries and offers a comprehensive portfolio of products aimed at nerve repair and regeneration.
Read more →AXGNAxogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Axogen, Inc. announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs, effective February 3, 2025. With over 13 years of experience in regulatory strategy within the biopharma sector, Bishop will oversee the company's regulatory affairs and related initiatives. His expertise is seen as critical for advancing Axogen's product development and regulatory strategies in the field of peripheral nerve repair. Additionally, he will receive an equity grant of 45,000 shares subject to a four-year vesting schedule.
Read more →AXGN▲ +18.2%on this news
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Axogen, Inc. has announced the appointment of Craig Swandal as Vice President of Operations, effective January 9, 2025. Swandal, who has over 25 years of experience in global manufacturing, will oversee all aspects of the company’s operations, which include manufacturing and supply chain strategies. In connection with his appointment, he will receive an equity inducement grant consisting of Restricted Stock Units and Performance Stock Units, aimed at aligning his performance with company stock price goals. This move is expected to enhance Axogen's commitment to developing surgical solutions for peripheral nerve injuries.
Read more →AXGN▲ +18.2%on this news
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
Axogen, Inc. reported preliminary unaudited revenue for the fourth quarter and full year of 2024, highlighting a significant growth in revenue. The company expects fourth quarter revenue to be approximately $49.4 million and full year revenue around $187.3 million, both reflecting substantial increases compared to previous years. Axogen's performance is credited to effective commercial strategies and product adoption, particularly in peripheral nerve surgical applications. Looking ahead, an Investor Day is planned for March 4, 2025, to outline strategic priorities.
Read more →AXGN▼ -13.4%on this news
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
Axogen, Inc. reported a successful third quarter for 2024 with a revenue increase of 17.9% and an adjusted net income of $3.1 million. The company also announced that the FDA accepted its Biologics License Application for the Avance Nerve Graft, setting a PDUFA goal date for September 2025. However, gross margins suffered a slight decrease, and the company still faces net losses despite improvements. Axogen maintains its full-year revenue guidance of $182 million to $186 million and aims to achieve net cash flow positivity by year-end.
Read more →AXGNAxogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
Axogen, Inc. (NASDAQ: AXGN) announced it will report its third quarter 2024 financial results on November 7, 2024, before the market opens. Following the release, the company will host a conference call and webcast at 8 a.m. ET. Investors can participate via phone or listen through the company's website. Axogen is recognized for its dedication to developing and marketing solutions for peripheral nerve repair.
Read more →AXGNAxogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft
Axogen, Inc. has successfully completed the rolling submission of its Biologics License Application for the Avance Nerve Graft to the FDA. The company is optimistic about obtaining a priority review status, which may shorten the approval timeline. The FDA had previously designated Avance as a Regenerative Medicine Advanced Therapy, indicating its potential to treat serious nerve injuries. However, the timeline for approval remains uncertain and relies on the FDA's decision-making process.
Read more →AXGNAxogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
Axogen, Inc. announced an equity inducement award for a new employee under NASDAQ Listing Rule 5635(c)(4). The award consists of 10,000 restricted stock units that vest over four years. This move demonstrates Axogen's commitment to attracting qualified individuals to bolster its workforce as it focuses on innovative surgical solutions for peripheral nerve injuries. The company emphasizes its leadership in the field and the importance of providing effective repair solutions for patients.
Read more →AXGNAxogen, Inc. Announces New Leadership Appointments The Board of Directors appoints Michael Dale as new CEO and Director, effective
Axogen, Inc. has announced the appointment of Michael Dale as the new CEO and member of the Board of Directors, effective August 9, 2024. Dale succeeds Karen Zaderej, who will serve in an advisory role for the next nine months. His appointment is seen as a strategic move to align Axogen's leadership with its goals of commercial expansion and profitability. Additionally, Paul Thomas has been named Chairman of the Board, reflecting a commitment to advancing the company's mission in peripheral nerve repair.
Read more →AXGN▲ +35.1%on this newsshared move
Axogen, Inc. Reports Second Quarter 2024 Financial Results
Axogen, Inc. reported strong financial results for the second quarter of 2024, showcasing a 25.6% increase in revenue to $47.9 million. Although the gross margin decreased to 73.8%, the company achieved an adjusted net income of $2 million, contrasting with a loss in the same period last year. They have successfully initiated the rolling submission process of their Biologics License Application for Avance Nerve Graft, predicting a potential mid-2025 approval. Additionally, Axogen has increased its annual revenue guidance, reflecting positive growth prospects.
Read more →AXGN▲ +35.1%on this newsshared move
Axogen, Inc. Announces New Leadership Appointments
Axogen, Inc. has appointed Michael Dale as the new CEO and Director, effective August 9, 2024, succeeding Karen Zaderej, who will continue in an advisory role. The Board believes this leadership change aligns with the company’s strategy for commercial growth and profitability. Paul Thomas will assume the role of Chairman of the Board also effective August 9, 2024. Dale's extensive background in medical technology is expected to propel Axogen's efforts in advancing nerve repair solutions.
Read more →AXGNAxogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Axogen, Inc. is set to report its financial results for the second quarter of 2024 on August 8, 2024. The announcement includes hosting a conference call with the investment community to discuss the results. Axogen specializes in surgical solutions for peripheral nerve injuries and has developed a range of products for nerve repair. The company's innovative technologies aim to improve the recovery and quality of life for patients affected by peripheral nerve damage.
Read more →AXGNAxogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
Axogen, Inc. has officially launched its latest product, the Avive+ Soft Tissue Matrix™, designed to aid in the healing of peripheral nerve injuries. This innovative multi-layer amniotic membrane allograft serves as a temporary barrier for tissue protection during recovery. The introduction of Avive+ aims to fulfill a significant need in the nerve repair market, which is estimated at approximately $800 million. Leading figures in the medical community, including CEO Karen Zaderej, emphasize the product's potential to enhance surgical outcomes for patients. Axogen continues to solidify its position as a frontrunner in the field of peripheral nerve regeneration and repair.
Read more →AXGN▲ +5.9%on this news
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Axogen, Inc. announced the opening of its Axogen Processing Center (APC) in Vandalia, Ohio, scheduled for June 12, 2024. This state-of-the-art facility, covering 107,000 sq. ft., is designed to enhance the processing capacity of Avance Nerve Graft, which aids in peripheral nerve repair. The center is expected to meet stringent regulatory standards as it transitions Avance to a biologic classification, positioning Axogen for significant future growth. The event will include an opening ceremony featuring key speakers from Axogen and the local community.
Read more →AXGNAxogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft
Axogen Inc. has commenced the rolling submission of the Biologics License Application (BLA) for its Avance Nerve Graft to the U.S. FDA. This process, started on May 15, 2024, includes a comprehensive non-clinical data package with plans for further submissions. The Avance Nerve Graft has received Regenerative Medicine Advanced Therapy (RMAT) designation, enhancing its development prospects and eligibility for priority review. Axogen anticipates completing the BLA submission by the third quarter of 2024 and aims for regulatory approval by mid-2025.
Read more →AXGNAxogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
Axogen, Inc., a leader in peripheral nerve recovery solutions, announced that its CEO, Karen Zaderej, will participate in the Leerink Partners Healthcare Crossroads Conference on May 29, 2024. The event will feature a fireside chat discussing the company's innovative approaches to nerve repair. Axogen's strong portfolio includes products designed for various surgical applications, emphasizing its role in improving patient outcomes related to peripheral nerve injuries.
Read more →AXGN▼ -10.4%on this news
Axogen, Inc Reports First Quarter 2024 Financial Results
Axogen, Inc. reported a 12.9% revenue increase for the first quarter of 2024, totaling $41.4 million. The company enhanced its gross margin to 78.8% and reduced its adjusted net loss to $2.7 million. A significant milestone includes the upcoming national launch of the Avive+ Soft Tissue Matrix in June and expected completion of the rolling BLA submission for Avance Nerve Graft® by Q3 2024. Despite achieving these positives, Axogen also reported a net loss of $6.6 million and a decrease in cash reserves.
Read more →AXGNAxogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
Axogen, Inc. has announced the first surgical implantations of its new Avive+ Soft Tissue Matrix, aimed at supporting healing in nerve injuries. This resorbable, multi-layer allograft has received positive initial feedback from surgeons. The company is set to launch Avive+ nationally in the second quarter of 2024. This advancement is expected to fill a notable gap in nerve protection methods during surgical procedures.
Read more →AXGNAxogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Axogen, Inc. (NASDAQ: AXGN) announced it will report its first quarter 2024 financial results on May 2, 2024, before market opens. Following the release, management will host a conference call at 8 a.m. ET for investors and interested parties. Axogen specializes in surgical solutions for peripheral nerve injuries and offers a wide range of products for both scheduled and emergent procedures. The company's focus is on restoring nerve function and improving patient quality of life.
Read more →AXGN▼ -15.1%on this news
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. reported financial results for Q4 and full-year 2023, showing strong revenue growth of 18.7% in the fourth quarter, totaling $42.9 million. The company's full-year revenue rose 14.7% to $159 million, driven by increases in both emergent and scheduled procedures. Despite a net loss of $21.7 million for the year, Axogen is optimistic about future growth, particularly with the upcoming launch of its Avive+ Sofit Tissue Matrix product. The company also highlights its cash position and operational advancements as indicators of continued progress.
Read more →AXGNAxogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
Axogen, Inc. has announced that it will release its financial results for the fourth quarter and full-year of 2023 on March 5, 2024, before the market opens. Following the release, management will host a conference call and webcast for the investment community at 8 a.m. ET. Axogen is recognized for its advancements in surgical solutions for peripheral nerve injuries, aiming to improve patient quality of life through various innovative products.
Read more →AXGNAxogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
Axogen, Inc. announced positive topline results from its REPOSE clinical trial, which demonstrated that Axoguard Nerve Cap is statistically superior to standard-of-care neurectomy in reducing pain. The trial met its primary endpoint for non-inferiority and provided evidence that the Axoguard Nerve Cap could significantly help patients suffering from symptomatic neuroma. These outcomes support the potential adoption of Axoguard Nerve Cap among healthcare providers for improved patient recovery. The trial's findings add to the body of clinical evidence on the benefits of this innovative surgical solution.
Read more →AXGNAxogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
Axogen, Inc. has announced that CEO Karen Zaderej plans to retire by January 2025, with the Board starting a search for her successor. During the transition, Zaderej will act as a consultant for nine months to facilitate the leadership change and support the BLA submission for the Avance® Nerve Graft. Under her leadership, Axogen has grown significantly, reporting preliminary revenue of approximately $158.8 million for 2023, reflecting a solid year-over-year increase. The company is well-positioned for growth as it shifts focus toward post-BLA commercial strategies.
Read more →AXGNAxogen Announces Promotions on Research and Development Team
Axogen, Inc. has announced the promotions of three members of its research and development team, including Erick DeVinney as Chief Innovation Officer, Ivica Ducic as Chief Medical Officer, and Stacy Arnold as Vice President of Product Development and Clinical Research. These promotions signify the company's focus on leveraging its internal talent to enhance innovation and ensure continuity as it progresses through the BLA submission process for its Avance® Nerve Graft. Concurrently, the company also announced the impending departure of Angelo Scopelianos, the Chief Research and Development Officer, which may lead to transitional challenges.
Read more →AXGNAxogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
Axogen, Inc. has announced preliminary unaudited revenue figures for the fourth quarter and full-year 2023, showcasing significant growth. Revenue for Q4 is projected at $42.7 million, an 18% increase compared to the same period in 2022, while full-year revenue is expected to reach $158.8 million, a 15% growth from the previous year. Key drivers of this growth include the successful introduction of new products and an increase in core accounts. The company plans to provide complete audited results on March 5, 2024.
Read more →AXGNAxogen, Inc. Appoints Kathy Weiler to its Board of Directors
Axogen, Inc. has appointed Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler brings over 20 years of experience in strategic commercial initiatives from her roles at companies like Amwell and Optum. She will contribute to the Governance and Sustainability Committee and the Quality, Compliance, and Portfolio Management Committee. The addition of Weiler is seen as a pivotal moment for Axogen as they aim to improve patient activation and commercial execution.
Read more →AXGN▲ +5.2%on this news
Axogen Announces Transition of Finance Team Leadership
Axogen, Inc. has appointed Nir Naor as the new Chief Financial Officer, succeeding Peter Mariani. This leadership change is aimed at aligning the finance team with the company's strategic focus on revenue growth and profitability. Axogen maintains its 2023 revenue guidance, projecting an annual increase of 11% to 15%. However, the company does anticipate a reduction in gross margin during the transition to a new processing facility.
Read more →AXGNAxogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference
Axogen, Inc. announced its participation at the Piper Sandler 35th Annual Healthcare Conference, which will occur on November 30, 2023. CEO Karen Zaderej will present at the event, highlighting Axogen's commitment to advancing surgical solutions for peripheral nerve injuries. The company is recognized as a leader in the development and marketing of technologies aimed at peripheral nerve regeneration and repair. Axogen's innovative product portfolio supports both scheduled and emergent procedures, emphasizing its impact on patient recovery and quality of life.
Read more →AXGN▲ +36.9%on this news
Axogen, Inc. Reports 2023 Third Quarter Financial Results
Axogen, Inc. reported its financial results for the third quarter of 2023, highlighting a 12% revenue increase to $41.3 million compared to Q3 2022. The company's adjusted net income improved to $0.7 million, and it has seen growth in both emergent trauma and scheduled non-trauma procedures. Management expressed confidence in their strategic initiatives and product launches, projecting continued growth for the remainder of the year. Additionally, Axogen anticipates a Pre-BLA meeting with the FDA in early Q1 2024 regarding its Avance nerve graft.
Read more →AXGNAxogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
Axogen, Inc. has announced that it will report its financial results for the third quarter of 2023 on November 7, 2023, prior to market opening. Following the results, the company will host a conference call for the investment community at 8:00 a.m. ET. Axogen specializes in surgical solutions for peripheral nerve injuries and aims to improve the lives of patients affected by nerve damage. The upcoming report will provide stakeholders with insights into the company's financial performance and future outlook.
Read more →AXGNAxogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™
Axogen, Inc. has announced the full launch of Axoguard HA+ Nerve Protector, which enhances their existing nerve protection platform. The new device, featuring a unique hyaluronate-alginate gel coating, offers both short- and long-term protection for various peripheral nerve injuries. Surgeons can leverage this product to address more complex challenges during critical healing phases, particularly for injuries near mobile joints. This launch emphasizes Axogen's commitment to advancing treatment options in the field of peripheral nerve repair.
Read more →AXGNAxogen to Participate at Upcoming Investor Conferences
Axogen, Inc. (NASDAQ: AXGN) is set to participate in two key investor conferences in September, featuring CEO Karen Zaderej. The first event, the H.C. Wainwright 25th Annual Global Investment Conference, will take place on September 11 in New York. Following this, Zaderej will partake in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on September 28. The company is recognized for its innovative solutions in peripheral nerve injury repair and its products are available in various countries.
Read more →AXGNAxogen, Inc. Begins Processing Avance Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio
Axogen, Inc. has initiated processing of the Avance Nerve Graft at its newly opened Axogen Processing Center in Dayton, Ohio. This state-of-the-art facility enhances its ability to support a Biologics License Application (BLA) submission scheduled for the first half of 2024. The new center, encompassing 107,000 square feet, offers advanced clean rooms and increased production capacity, positioning Axogen for long-term growth in the peripheral nerve market. The company highlighted its commitment to improving surgical solutions for patients dealing with nerve injuries.
Read more →AXGNAxogen, Inc. Reports 2023 Second Quarter Financial Results
Axogen, Inc. reported its second-quarter financial results, demonstrating a revenue increase of 11% year-over-year. The company also noted successful growth in scheduled non-trauma procedures, while emergent trauma procedures faced challenges due to hospital resource allocation. Additionally, the company announced the pilot launch of the Axoguard HA+ Nerve Protector and positive results from the Phase 3 RECON study, which supports its future BLA submission plans. Despite a net loss, Axogen maintains a positive outlook with full-year revenue guidance remaining unchanged.
Read more →AXGN▼ -6.8%on this news
Axogen to Participate at Canaccord Genuity’s 43rd Annual Growth Conference
Axogen, Inc. (NASDAQ: AXGN) announced its participation in Canaccord Genuity’s 43rd Annual Growth Conference on August 9, 2023. CEO Karen Zaderej will engage in a fireside chat to discuss the company’s innovative solutions for peripheral nerve injuries. Axogen is recognized for its dedication to pioneering technologies that aid in peripheral nerve repair, with a strong product portfolio available internationally. This event provides an opportunity for investors to learn more about Axogen's advancements and contributions in the field.
Read more →AXGNAxogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023
Axogen, Inc. has announced that it will report its second quarter 2023 financial results on August 7, 2023, after the market closes. Following the release, the company will host a conference call and webcast at 4:30 p.m. ET for investors. Axogen focuses on surgical solutions for peripheral nerve injuries and has a diverse product portfolio aimed at improving patient outcomes and quality of life.
Read more →AXGNAxogen to Participate at Jefferies Healthcare Conference
Axogen, Inc. announced its participation at the Jefferies Healthcare Conference, where CEO Karen Zaderej will engage in a fireside chat on June 7, 2023. The event aims to showcase Axogen's advancements in surgical solutions for peripheral nerve injuries. The company emphasizes its role as a leader in the development of effective technologies for nerve regeneration and repair. Axogen's products are available in multiple countries, showcasing the company's international reach in the healthcare sector.
Read more →AXGNAxogen to Participate at JMP Securities Life Sciences Conference
Axogen, Inc. (NASDAQ: AXGN) will participate in the JMP Securities Life Sciences Conference on May 15, 2023. During the event, Peter Mariani, the company's Executive Vice President & CFO, will engage in a fireside chat. Axogen is recognized for its innovative surgical solutions aimed at addressing peripheral nerve injuries, and their products are designed to improve patient outcomes. The webcast can be accessed through Axogen's Investors page for those interested in the discussion.
Read more →AXGNAxogen, Inc. Reports 2023 First Quarter Financial Results
Axogen, Inc. reported a first-quarter revenue increase of 18% year-over-year, amounting to $36.7 million. Although the company reported a net loss of $7.1 million, this was an improvement compared to the previous year's loss of $11.5 million. Notably, the company received FDA clearance for its new Axoguard HA+ Nerve Protector, which will pilot launch in the upcoming quarter. Axogen's financial guidance for 2023 anticipates revenues between $154 million and $159 million, while the gross margin is expected to reduce due to transitioning to a new processing facility.
Read more →AXGNAxogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023
Axogen, Inc. (AXGN) is set to report its first quarter 2023 financial results on May 9, 2023, prior to market opening. Following the results, the company will host a conference call at 8:00 a.m. ET for the investment community. Axogen specializes in developing surgical solutions for peripheral nerve injuries, emphasizing innovative and clinically proven products for nerve repair. Its portfolio includes several notable products designed to improve patient outcomes after nerve damage.
Read more →AXGN▲ +12%on this news
Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. reported its financial results for the fourth quarter and full-year 2022, achieving a 17% increase in revenue to $36.2 million. The adjusted net loss for the quarter was reduced to $1.1 million, showcasing improved financial performance compared to the previous year. Despite these improvements, the company anticipates a decline in gross margins in the first half of 2023 due to the transition to a new processing facility. Additionally, Axogen maintains significant cash reserves and plans to enhance operational banking arrangements.
Read more →AXGNAxogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel
Axogen, Inc. has appointed Marc Began as its new Executive Vice President and General Counsel, effective March 20, 2023. Began replaces Brad Ottinger and will oversee all legal, business development, and compliance activities as part of the executive leadership team. He brings over 20 years of experience in the biotechnology sector, having previously held significant roles at Abiomed and Boehringer Ingelheim. Along with Began's appointment, the company has announced inducement grants connected to his and the new Chief Marketing Officer's employment.
Read more →AXGNAxogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023
Axogen, Inc. announced it will report its fourth quarter 2022 financial results on March 14, 2023, before the market opens. Following the release, the company will host a conference call and webcast for the investment community at 8:00 a.m. ET. Axogen specializes in surgical solutions for peripheral nerve injuries, showcasing its advanced product lineup aimed at improving patient outcomes in this area.
Read more →AXGNAxogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer
Axogen, Inc. has appointed Jens Schroeder Kemp as its Chief Marketing Officer, a newly created role aimed at enhancing the company's marketing strategies for its nerve repair solutions. With over 20 years of experience in the medical technology sector, Kemp previously held senior marketing positions at Ambu Inc., where he successfully developed market strategies. His role at Axogen will involve driving surgeon adoption and fostering innovation within the company's clinical portfolio. The appointment comes at a pivotal time for Axogen, as it aims to continue advancing its products that assist in peripheral nerve regeneration.
Read more →AXGNAxogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
Axogen, Inc. reported preliminary unaudited revenue figures for the fourth quarter and full-year 2022, anticipating a 16% increase in fourth-quarter revenue to approximately $36.1 million. Full-year 2022 revenue estimates stand at about $138.5 million, reflecting a 12% growth over the previous year. The company also noted an increase in both Core Accounts and Active Accounts, demonstrating ongoing market adoption of its products. Axogen is also preparing to transition to a new processing facility and plans to submit a Biologics License Application for its Avance Nerve Graft later in 2023.
Read more →AXGN▲ +5.5%on this newsshared move
Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and Conduits
Axogen, Inc. has announced the publication of a meta-analysis comparing the effectiveness of allograft, autograft, and conduits for nerve gap repair. The analysis, which drew from 35 peer-reviewed studies, concluded that recovery rates for allograft and autograft are similar across various gap lengths. It also highlighted the Avance Nerve Graft as an effective alternative that does not require donor site harvesting, potentially reducing complications for patients. This evidence reinforces Axogen’s position in nerve repair technologies.
Read more →AXGNAxogen to Participate at J.P. Morgan 41st Annual Healthcare Conference
Axogen, Inc. will have its CEO, Karen Zaderej, present at the J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023. The company is known for its innovative surgical solutions for peripheral nerve injuries and plans to showcase its advancements during the presentation. The event will include a live webcast and an archived replay available for 90 days. Axogen's products focus on restoring function and quality of life for patients with nerve damage.
Read more →AXGNAxogen Patient to Ride the 2023 Donate Life Rose Parade Float Supporting awareness of organ and tissue donation
ALACHUA, Fla. and TAMPA, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Bri Majsiak, a Resensation® patient, has been selected to ri
Read more →AXGN▲ +12.9%on this news
Axogen, Inc Reports 2022 Third Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter en
Read more →AXGNAxogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.
ALACHUA, Fla. and TAMPA, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that effective December 13, 2022 (the “Effective Date”), Adrian T
Read more →AXGNAxogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022
ALACHUA and TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2022 financial results on Tuesday, No
Read more →AXGNAxogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand
ALACHUA and TAMPA, Fla., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that it will participate in the 77th Annual Meeting of th
Read more →AXGNAxogen, Inc Reports 2022 Second Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter e
Read more →AXGNAxogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference
ALACHUA. Fla. and TAMPA, Fla, July 29, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at
Read more →AXGNAxogen, Inc. Announces Organizational Updates, Preliminary Second Quarter Revenue and Reaffirms Full-Year 2022 Financial Guidance Organizational updates are part of plan to bring additional focus on leveraging clinical d
Axogen, Inc. Announces Organizational Updates, Preliminary Second Quarter Revenue and Reaffirms Full-Year 2022 Financial Guidance Organizational updates are part of plan to bring additional focus on leveraging clinical data to accelerate market development and the pace Prelimin
Read more →AXGNAxogen, Inc. Appoints William Burke to Board of Directors Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of Directors ALACHUA and TAMPA, FL
Axogen, Inc. Appoints William Burke to Board of Directors Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of Directors ALACHUA and TAMPA, FL - July 11, 2022 - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing in
Read more →AXGNAxogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference
ALACHUA, Fla. and TAMPA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president and Peter J. Mari
Read more →AXGNAxogen, Inc Reports 2022 First Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter end
Read more →AXGNAxogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance Nerve Graft
ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced topline results from its RECON Clinical Study comparing Avance Ner
Read more →AXGNAxogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022
ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2022 financial results on Wedn
Read more →AXGN▲ +11.2%on this news
Axogen, Inc. publishes inaugural ESG Report
ALACHUA, Fla. and TAMPA, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today published its inaugural Environmental, Social, and Governance (ESG) report
Read more →AXGNAxogen, Inc. Reports 2021 Fourth Quarter and Full-Year Financial Results
ALACHUA, Fla. and TAMPA, Fla., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter a
Read more →AXGNAxogen, Inc. to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on February 22, 2022
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter and full-year 2021 financial r
Read more →AXGNAxogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021
ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2021 revenue.
Read more →AXGNAxogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2022 meetings
Read more →AXGNAxogen sponsors 2022 Donate Life Rose Parade Float to help raise awareness of organ and tissue donation
ALACHUA, Fla. and TAMPA, Fla., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today that nerve repair patient Christopher (Chris) Br
Read more →AXGNAxogen, Inc. to Participate at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
ALACHUA, Fla. and TAMPA, Fla., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and president, will present at
Read more →AXGN▼ -15.3%on this news
Axogen, Inc. to Participate at Jefferies London Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO and president, will present at
Read more →AXGNAxogen, Inc. Reports 2021 Third Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter en
Read more →AXGNAxogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021
ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2021 financial
Read more →AXGNAxogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand
ALACHUA, Fla. and TAMPA, Fla., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that it will participate in the 76th Annual Meeting
Read more →AXGNAxogen RECON(SM) Clinical Study Completes Subject Follow-up RECON is a pivotal study supporting the Company s Biologics License Application (BLA) for Avance Nerve Graft ALACHUA, Fla. and
Axogen RECON(SM) Clinical Study Completes Subject Follow-up RECON is a pivotal study supporting the Company s Biologics License Application (BLA) for ALACHUA, Fla. and TAMPA, Fla., Sept. 01, 2021 (GLOBE NEWSWIRE) Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
Read more →AXGNAxogen, Inc. Reports 2021 Second Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter e
Read more →AXGNAxogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and preside
Read more →AXGNAxogen, Inc. Appoints John H. Johnson to Board of Directors
ALACHUA, Fla. and TAMPA, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed to its
Read more →AXGNAxogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021
ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financia
Read more →AXGNAxogen, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference
ALACHUA, Fla. and TAMPA, Fla. , May 06, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Peter J. Mariani, executive vice preside
Read more →AXGNAxogen, Inc. Reports 2021 First Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter end
Read more →AXGNAxogen, Inc. to Report First Quarter Financial Results and Host Conference Call on May 5, 2021
ALACHUA Fla. and TAMPA, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2021 financial
Read more →AXGNAxogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer
ALACHUA, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the promotion of Peter J. Mariani to Executive Vice President and Chief Financia
Read more →AXGNAxogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results
ALACHUA, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year end
Read more →AXGNAxogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis
ALACHUA, Fla., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of pilot phase analysis for its REPOSE clinical study
Read more →AXGNAxogen, Inc. to Participate at Upcoming February Investor Conferences
ALACHUA, Fla., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced it will participate in two investor conferences in February.
Read more →AXGNAxogen, Inc. to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call on February 22, 2021
ALACHUA, Fla., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report fourth quarter and full-year 2020 financial
Read more →AXGNAxogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2020 ALACHUA, FL
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2020 ALACHUA, FL - January 11, 2021 - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary
Read more →AXGNAxogen to Participate at AAHS ASPN ASRM 2021 Virtual Annual Meetings
ALACHUA, Fla., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2021 meetings of the American
Read more →AXGNAxogen Sponsors Donate Life at 2021 Virtual Rose Parade Celebration
ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today their sponsorship of Donate Life at the annual Tournament of Ros
Read more →AXGNAxogen, Inc. to Participate at Jefferies Virtual London Healthcare Conference and Canaccord Genuity Virtual MedTech & Diagnostics Forum
ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present a
Read more →AXGNAxogen, Inc. Reports Third Quarter 2020 Financial Results ALACHUA, FL
Axogen, Inc. Reports Third Quarter 2020 Financial Results ALACHUA, FL - October 29, 2020 - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highligh
Read more →AXGNAxogen, Inc. to Report Third Quarter 2020 Financial Results and Host Conference Call on October 29, 2020
ALACHUA, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report third quarter 2020 financial results on Thur
Read more →AXGNAxogen, Inc. Appoints Paul G. Thomas to Board of Directors Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors ALACHUA, FL
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors ALACHUA, FL - September 30, 2020 - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgica
Read more →AXGNAxogen, Inc. to Present at the JMP Securities MedTech Bio Summit
ALACHUA, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will presen
Read more →AXGNAxogen to Participate in the 75th Annual American Society for Surgery of the Hand Meeting
ALACHUA, Fla., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that it will participate in the 75th Annual Meeting of the American
Read more →AXGNAxogen, Inc. to Present at the Cantor Virtual Global Healthcare Conference
ALACHUA, Fla., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present
Read more →AXGNAxogen, Inc. Reports Second Quarter 2020 Financial Results ALACHUA, FL
Axogen, Inc. Reports Second Quarter 2020 Financial Results ALACHUA, FL - August 5, 2020 - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlight
Read more →AXGNAxogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
ALACHUA, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present
Read more →AXGNAxogen RECON SM Clinical Study Completes Target Enrollment of 220 Subjects RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance Nerve Graft ALACHUA, FL
Axogen RECONSM Clinical Study Completes Target Enrollment of 220 Subjects RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance Nerve Graft ALACHUA, FL - July 22, 2020 - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and m
Read more →AXGNAxogen RECON Clinical Study Completes Target Enrollment of 220 Subjects
ALACHUA, Fla., July 22, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that its phase 3 pivotal RECONSM Clinical Study supporting its B
Read more →AXGNAxogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020
ALACHUA, Fla., July 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today confirmed that it will report second quarter 2020 financial results on Wed
Read more →AXGNAxogen Announces New Seven-Year Financing Agreement with Oberland Capital and Provides Preliminary Second Quarter Revenue Estimate ALACHUA, FL
Axogen Announces New Seven-Year Financing Agreement with Oberland Capital and Provides Preliminary Second Quarter Revenue Estimate ALACHUA, FL - July 1, 2020 - Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral n
Read more →AXGNAxogen, Inc. Announces Planned Retirement of Greg Freitag and Appoints Brad Ottinger as General Counsel and Chief Compliance Officer Freitag will continue as member of board of directors and serve as special counsel in t
Axogen, Inc. Announces Planned Retirement of Greg Freitag and Appoints Brad Ottinger as General Counsel and Chief Compliance Officer Freitag will continue as member of board of directors and serve as special counsel in transitional role through October ALACHUA, FL June 1, 202
Read more →AXGNAxogen, Inc. to Present at the Jefferies Virtual Healthcare Conference
ALACHUA, Fla., May 20, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present a
Read more →AXGNAxogen, Inc. Reports First Quarter 2020 Financial Results ALACHUA, FL –
Axogen, Inc. Reports First Quarter 2020 Financial Results ALACHUA, FL May 6, 2020 Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for th
Read more →AXGNAxogen, Inc. Reports Preliminary Revenue for the First Quarter 2020, Provides Business Update in Response to COVID-19 Pandemic, and Announces Dismissal of Class Action Lawsuit ALACHUA, FL –
Axogen, Inc. Reports Preliminary Revenue for the First Quarter 2020, Provides Business Update in Response to COVID-19 Pandemic, and Announces Dismissal of Class Action Lawsuit ALACHUA, FL April 23, 2020 Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing i
Read more →AXGNAxogen, Inc. Reports Preliminary Revenue for the First Quarter 2020, Provides Business Update in Response to COVID-19 Pandemic, and Announces Dismissal of Class Action Lawsuit
ALACHUA, Fla., April 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary first quarter 2020 revenue, provided a business update on its action
Read more →AXGNAxogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020
ALACHUA, Fla., April 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2020 financial results on Wed
Read more →AXGNAxogen, Inc. to Participate at Upcoming Investor Conferences
ALACHUA, Fla., March 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that members of its management team will participate in two i
Read more →AXGNAxogen, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results ALACHUA, FL –
Axogen, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results ALACHUA, FL February 24, 2020 Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and busi
Read more →AXGNAxogen, Inc. to Present at the Leerink Partners 9th Annual Global Healthcare Conference
ALACHUA, Fla., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present
Read more →AXGNAxogen, Inc. to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call on February 24, 2020
ALACHUA, Fla., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report fourth quarter and full-year 2019 financial
Read more →AXGNThis press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2019 and Provides 2020 Annual Guidance ALACHUA, FL January 13, 2020 Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,
Read more →AXGNAxogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2019 and Provides 2020 Annual Guidance
ALACHUA, Fla., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2019 revenue. Preliminary Una
Read more →AXGNAxogen Sponsored RANGER Registry Reaches 2,000 Nerve Repair Enrollment Milestone
ALACHUA, Fla., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that its RANGER registry enrollment has reached the milestone of
Read more →AXGNAxogen to Participate at AAHS ASPN ASRM 2020 Annual Meetings
ALACHUA, Fla., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2020 meetings of the American
Read more →AXGNAxogen, Inc. to Participate at JP Morgan 38th Annual Healthcare Conference
ALACHUA, Fla., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present a
Read more →AXGNAxogen awarded research grant from the Advanced Regenerative Manufacturing Institute
Company will develop an automated bioprocessing system for human tissue scaffolds ALACHUA, Fla., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerve
Read more →AXGNAxogen, Inc. to Participate at Piper Jaffray 31st Annual Healthcare Conference
ALACHUA, Fla., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present a
Read more →AXGNAxogen, Inc. Reports 2019 Third Quarter Financial Results ALACHUA, FL –
Axogen, Inc. Reports 2019 Third Quarter Financial Results ALACHUA, FL November 6, 2019 Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today reported financial results and busi
Read more →AXGNAxogen, Inc. to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019
ALACHUA, Fla., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2019 financial results on Wedn
Read more →AXGNAxogen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
ALACHUA, Fla., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, chief executive officer, and pr
Read more →AXGNAxogen to Participate in the 74th Annual American Society for Surgery of the Hand Meeting
Updated outcomes data from the RANGER® Registry’s MATCHSM cohort will be presented during scientific sessions ALACHUA, Fla., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or dis
Read more →AXGNAxogen, Inc. Reports 2019 Second Quarter Financial Results Second Quarter Revenue of $26.7 million, Representing 30% Growth Versus Second Quarter 2018 ALACHUA, FL –
Axogen, Inc. Reports 2019 Second Quarter Financial Results Second Quarter Revenue of $26.7 million, Representing 30% Growth Versus Second Quarter 2018 ALACHUA, FL August 6, 2019 Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutio
Read more →AXGNAxogen, Inc. to Participate at Canaccord Genuity 39th Annual Growth Conference
ALACHUA, Fla., July 29, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Peter J. Mariani, chief financial officer, will present at
Read more →AXGNAxogen Announces Publication of the 100th Peer-Reviewed Clinical Paper Featuring its Product Portfolio for Peripheral Nerve Repair
ALACHUA, Fla., July 26, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced publication of the 100th peer-reviewed paper featuring results f
Read more →AXGNAxogen, Inc. to Report Second Quarter 2019 Financial Results and Host Conference Call on August 6, 2019
ALACHUA, Fla., July 23, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2019 financial results on Tue
Read more →AXGNAxogen, Inc. Reports 2019 First Quarter Financial Results First Quarter Revenue of $23.3 million, representing 35% growth versus first quarter 2018 ALACHUA, FL –
Axogen, Inc. Reports 2019 First Quarter Financial Results First Quarter Revenue of $23.3 million, representing 35% growth versus first quarter 2018 ALACHUA, FL May 8, 2019 Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for
Read more →AXGNAxogen, Inc. Appoints New Members to Board of Directors Quentin S. Blackford, Executive Vice President and Chief Financial Officer of Dexcom Alan M. Levine Chairman, President, and Chief Executive Officer for Ballad Heal
Axogen, Inc. Appoints New Members to Board of Directors Quentin S. Blackford, Executive Vice President and Chief Financial Officer of Dexcom Alan M. Levine Chairman, President, and Chief Executive Officer for Ballad Health New members bring a breadth of healthcare leadership
Read more →AXGNinflammation in the surgical bed. Along with these core surgical products, Axogen also offers Acroval ® Neurosensory & Motor Testing System and Axotouch ® Two-Point Discriminator. These evaluation and measureme
Axogen, Inc. to Report First Quarter 2019 Financial Results and Host Conference Call on May 8, 2019 ALACHUA, FL April 22, 2019 Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves,
Read more →AXGNAxogen, Inc. Announces Completion of Planned Interim Analysis and One-Time Enrollment Expansion for RECON Study
ALACHUA, Fla., April 22, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of the planned blinded interim analysis for its RECO
Read more →AXGNAxogen, Inc. to Report First Quarter 2019 Financial Results and Host Conference Call on May 8, 2019
ALACHUA, Fla., April 22, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2019 financial results on Wed
Read more →AXGNAxogen, Inc. to Participate at Upcoming March Investor Conferences
ALACHUA, Fla., March 04, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that members of its management team will participate in three i
Read more →AXGNAXOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AxoGen, Inc. - AXGN
NEW ORLEANS, March 01, 2019 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc. (NasdaqCM: AXGN), if they purch
Read more →AXGNAxogen Class Action Lawsuit: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Axogen, Inc. – AXGN
NEW YORK, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of AxoGen, Inc. (“AxoGen” or the “Compa
Read more →AXGNAxogen, Inc. Reports 2018 Fourth Quarter and Full Year 2018 Financial Results Fourth Quarter Revenue of $23.4 million, representing 38% growth over prior year Full year 2018 Revenue of $83.9 million, representing 39% gro
Axogen, Inc. Reports 2018 Fourth Quarter and Full Year 2018 Financial Results Fourth Quarter Revenue of $23.4 million, representing 38% growth over prior year Full year 2018 Revenue of $83.9 million, representing 39% growth over prior year ALACHUA, FL February 26, 2018 Axogen
Read more →AXGNAXOGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AxoGen, Inc. - AXGN
NEW ORLEANS, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit
Read more →AXGNAxogen, Inc. to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26, 2019
ALACHUA, Fla., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that it will report fourth quarter and full year 2018 financia
Read more →AXGNAxoGen to Participate at AAHS ASPN ASRM 2019 Annual Meetings
ALACHUA, Fla., Jan. 24, 2019 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced its participation at the combined 2019 Meetings of the America
Read more →AXGNsensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on peripheral nerve function. The AxoGen portfolio of products is available in the United States, Canada
AxoGen Appoints Eric Sandberg as Chief Commercial Officer Sandberg brings 25+ years of experience leading the commercialization of medical technologies ALACHUA, FL January 22, 2019 AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical sol
Read more →AXGNAxoGen Appoints Eric Sandberg as Chief Commercial Officer
ALACHUA, Fla., Jan. 22, 2019 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced the appointment of Eric Sandberg as Chief Commercial Officer.
Read more →AXGNAxoGen Announces RECON ® Study Update Study Supports Company's Planned Biologic License Application (BLA) for Avance ® Nerve Graft ALACHUA, FL –
AxoGen Announces RECON Study Update Study Supports Company's Planned Biologic License Application (BLA) for Avance Nerve Graft ALACHUA, FL January 15, 2019 AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or disco
Read more →AXGNAXOGEN INVESTOR ALERT: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm – AXGN
RADNOR, Pa., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN) on behalf of investors who purchased shares of the Company’s stock between August 7, 201
Read more →AXGNAxoGen Announces RECON Study Update
ALACHUA, Fla., Jan. 15, 2019 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that the RECON® Study supporting its Biologic License Applicat
Read more →AXGNAXOGEN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for Middle District of Florida against AxoGen, Inc.
NEW YORK, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for Middle District of Florida against AxoGen, Inc. ("AxoGen" or the “Company") (NASDAQ: AXGN) and certa
Read more →AXGNAxoGen Class Action Lawsuit: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against AxoGen, Inc. – AXGN
NEW YORK, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of AxoGen, Inc. (“AxoGen” or the “Compa
Read more →AXGNAxoGen, Inc. Pre-Announces Financial and Operational Results Q4 Revenue of at least $23.4 million, a 38% YoY increase FY 2018 Revenue of at least $83.9 million, a 39% YoY increase Company reaffirms 2019 financial guidanc
AxoGen, Inc. Pre-Announces Financial and Operational Results Q4 Revenue of at least $23.4 million, a 38% YoY increase FY 2018 Revenue of at least $83.9 million, a 39% YoY increase Company reaffirms 2019 financial guidance and provides business update Appoints Chris Crisman to
Read more →AXGNAxoGen Appoints Christopher Crisman as Vice President, U.S. Sales
ALACHUA, Fla., Jan. 07, 2019 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced the appointment of Christopher Crisman as Vice President, U.S.
Read more →AXGNAxoGen Losses Alert: Bernstein Liebhard LLP Announces First Investigation of AxoGen, Inc. - AXGN
NEW YORK, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN) resulting from allegations
Read more →AXGNAxoGen Announces Avance Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade Float
ALACHUA, Fla., Dec. 06, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Madelyn Nicpon was selected to ride on the 2019 Donate Li
Read more →AXGNAxoGen Advances its Platform for Nerve Repair at Annual Analyst and Investor Day
Updates Value of the Market Opportunity in Existing Applications from $2.2 Billion to $2.7 Billion Announces Market Development and Clinical Initiatives for Expanded Application in the Surgical Treatment of Chronic Neuropathic Pain ALACHUA, Fla., Nov. 19, 2018 (GLOBE NEWSWIRE)
Read more →AXGNAxoGen to Host Third Annual Analyst and Investor Day on November 19, 2018
ALACHUA, Fla., Nov. 06, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that it will host its Third Annual Analyst and Investor Day on
Read more →AXGNAxoGen, Inc. Reports 2018 Third Quarter Financial Results Q3 Revenue of $22.7 million, representing 41% growth over prior year; Management reiterates full year 2018 guidance and introduces 2019 guidance ALACHUA, FL  
AxoGen, Inc. Reports 2018 Third Quarter Financial Results Q3 Revenue of $22.7 million, representing 41% growth over prior year; Management reiterates full year 2018 guidance and introduces 2019 guidance ALACHUA, FL October 29, 2018 AxoGen, Inc. (NASDAQ: AXGN), a global leader
Read more →AXGNAxoGen, Inc. to Report Third Quarter 2018 Financial Results and Host Conference Call on October 29, 2018
ALACHUA, Fla., Oct. 16, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that it will report third quarter 2018 financial results on Mo
Read more →AXGNAxoGen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
ALACHUA, Fla., Sept. 24, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, chief executive officer, and pr
Read more →AXGNAxoGen to Participate at 73rd Annual American Society for Surgery of the Hand Meeting
Outcomes data for more than 400 nerve repairs with Avance® Nerve Graft will be reviewed at hosted symposium Data will highlight outcomes on sensory, mixed, motor, and long gap nerve repairs ALACHUA, Fla., Sept. 07, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global
Read more →AXGNAxoGen, Inc. Appoints Angelo G. Scopelianos, Ph.D. as Vice President, Research and Development ALACHUA, FL –
AxoGen, Inc. Appoints Angelo G. Scopelianos, Ph.D. as Vice President, Research and Development ALACHUA, FL September 4, 2018 AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves,
Read more →AXGNAxoGen, Inc. to Present at the Morgan Stanley Global Healthcare Conference
ALACHUA, Fla., Aug. 28, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Peter J. Mariani, chief financial officer, will present at the 16th Annual Morgan St
Read more →AXGNAxoGen, Inc. Reports 2018 Second Quarter Financial Results Q2 Revenue of $20.6 million, representing 36% growth over prior year; reiterates full year 2018 guidance ALACHUA, FL –
AxoGen, Inc. Reports 2018 Second Quarter Financial Results Q2 Revenue of $20.6 million, representing 36% growth over prior year; reiterates full year 2018 guidance ALACHUA, FL August 1, 2018 AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative sur
Read more →AXGNAxoGen, Inc. to Present at Canaccord Genuity Growth Conference
ALACHUA, Fla., July 25, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Peter J. Mariani, Chief Financial Officer, will present at the Canaccord Genuity Grow
Read more →AXGNAxoGen, Inc. to Report Second Quarter 2018 Financial Results and Host Conference Call on August 1, 2018
ALACHUA, Fla., July 24, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that it will report second quarter 2018 financial results on Wednesday, August 1, 2018 aft
Read more →AXGNAxoGen, Inc. Appoints Lisa N. Colleran to Board of Directors Health care industry veteran brings 30+ years of executive experience to AxoGen, Inc. Board of Directors ALACHUA, FL –
AxoGen, Inc. Appoints Lisa N. Colleran to Board of Directors Health care industry veteran brings 30+ years of executive experience to AxoGen, Inc. Board of Directors ALACHUA, FL July 10, 2018 AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative su
Read more →AXGNAxoGen Chairman and CEO Karen Zaderej Named Entrepreneur Of The Year 2018 Award Winner in Florida
ALACHUA, Fla., June 08, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Ernst & Young (EY) named AxoGen Chairman and CEO Karen Zaderej as the Entrepreneur Of
Read more →AXGNAxoGen, Inc. to Present at Upcoming Investor Conferences
William Blair 38th Annual Growth Stock Conference, June 14 JMP Securities Life Sciences Conference, June 20 ALACHUA, Fla., June 06, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerv
Read more →AXGNAxoGen, Inc. Appoints Kaila Krum Vice President, Investor Relations and Corporate Development
ALACHUA, Fla., June 04, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced the appointment of Kaila Krum to the newly created position of Vice President, Investor Re
Read more →AXGNAxoGen, Inc. Announces Repayment in Full of its $25 million Outstanding Debt
ALACHUA, Fla., May 29, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced that it repaid in full its outstanding debt with MidCap Financial (“MidCap”) on May 22, 2018. Th
Read more →AXGNAxoGen, Inc. to Present at the Jefferies Global Healthcare Conference
ALACHUA, Fla., May 23, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Karen Zaderej, president and CEO, will present at the Jefferies Global Healthcare Conf
Read more →AXGNAxoGen, Inc. Announces Appointment of Karen Zaderej as Chairman of the Board
ALACHUA, Fla., May 21, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that its Board of Directors has elected Karen Zaderej as Chairman of the Board in addition
Read more →AXGNAxoGen, Inc. Announces Closing of Public Offering of Common Stock
ALACHUA, Fla., May 14, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced the closing of its previously announced underwritten public offering of 3,450,000 shares of
Read more →AXGNAxoGen, Inc. Announces Upsizing and Pricing of Public Offering of Common Stock
ALACHUA, Fla., May 09, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced today that it has priced an underwritten public offering of 3,000,000 shares of its common stock,
Read more →AXGNAxoGen Announces Proposed Public Offering of Common Stock ALACHUA, FL
AxoGen Announces Proposed Public Offering of Common Stock ALACHUA, FL May 7, 2018 AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced today that it has commenced an underwritten public offering o
Read more →AXGNAxoGen, Inc. Reports 2018 First Quarter Financial Results Record Q1 Revenue of $17.3 million, representing 41% growth over prior year ALACHUA, FL –
AxoGen, Inc. Reports 2018 First Quarter Financial Results Record Q1 Revenue of $17.3 million, representing 41% growth over prior year ALACHUA, FL April 30, 2018 AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral
Read more →AXGNAxoGen, Inc. to Report First Quarter 2018 Financial Results and Host Conference Call on April 30, 2018
ALACHUA, Fla., April 18, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that it will report first quarter 2018 financial results on Monday, April 30, 2018 after
Read more →AXGNAxoGen, Inc. Announces 2018 Annual Shareholders’ Meeting
Monday, May 14, 2018 at 4:00 p.m. Eastern Time Hyatt Regency Orlando International Airport ALACHUA, Fla., April 12, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announ
Read more →AXGNAxoGen, Inc. Reports 2017 Fourth Quarter and Full Year Financial Results Record Q4 Revenue of $17.0 million, representing 49% growth over prior year Record Full year 2017 Revenue of $60.4 million, representing 47% growth
AxoGen, Inc. Reports 2017 Fourth Quarter and Full Year Financial Results Record Q4 Revenue of $17.0 million, representing 49% growth over prior year Record Full year 2017 Revenue of $60.4 million, representing 47% growth over prior year ALACHUA, FL February 28, 2018 AxoGen, I
Read more →AXGNAxoGen, Inc. to Present at 30th Annual ROTH Conference
ALACHUA, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Karen Zaderej, president and CEO, will present at the 30th Annual ROTH Conference in
Read more →AXGNAxoGen Named Employee Engagement Best Practices Award Winner by DecisionWise International
ALACHUA, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced it has received a 2018 Employee Engagement Best Practices Award. The annual award, sponsor
Read more →AXGNAxoGen, Inc. to Present at Canaccord Genuity Musculoskeletal Conference
ALACHUA, Fla., Feb. 20, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Peter J. Mariani, Chief Financial Officer, will present at the Canaccord Genuity Mus
Read more →AXGNAxoGen, Inc. to Report Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call on February 28, 2018
ALACHUA, Fla., Feb. 14, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve injuries, today announced that it will report fourth quarter and full-year 2017 financial res
Read more →AXGNAxoGen, Inc. to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
ALACHUA, Fla., Feb. 01, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, president and CEO, will present at the LEERINK Partners 7th An
Read more →AXGNAxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2017 Revenue Q4 Revenue will be at least $16.5 million, representing 45% growth over prior year 2017 Revenue will be at least $60.0 million, representing 4
AxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2017 Revenue Q4 Revenue will be at least $16.5 million, representing 45% growth over prior year 2017 Revenue will be at least $60.0 million, representing 46% growth over prior year ALACHUA, FL January 8, 2018 Ax
Read more →AXGNAxoGen to Participate at AAHS ASPN ASRM 2018 Annual Meetings
ALACHUA, Fla., Jan. 05, 2018 (GLOBE NEWSWIRE) -- AxoGen Corporation (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve damage, today announced its participation at the combined 2018 Meetings of the American Association fo
Read more →AXGNAxoGen Corporation Announces Avance Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade Float
ALACHUA, Fla., Dec. 18, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Dylan Harvey was selected to ride on the 2018 Donate Life Rose Parade® float
Read more →AXGNAxoGen Announces Closing of Public Offering of Common Stock
ALACHUA, Fla., Nov. 20, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve damage, today announced the closing of its previously announced underwritten public offering of 805,000 shar
Read more →AXGNAxoGen, Inc. (Nasdaq: AXGN) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Nov. 20, 2017 (GLOBE NEWSWIRE) -- AxoGen (Nasdaq:AXGN), a global leader in innovative surgical solutions for peripheral nerve regeneration and repair, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Karen Zaderej, President, CEO, Board Memb
Read more →AXGNAxoGen, Inc. Announces Pricing of Public Offering of Common Stock
ALACHUA, Fla., Nov. 16, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, announced today that it has priced an underwritten public offering of its common stock
Read more →AXGNAxoGen, Inc. Announces Proposed Public Offering of Common Stock
ALACHUA, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, announced today that it has commenced an underwritten public offering of its common st
Read more →AXGNAxoGen, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
ALACHUA, Fla., Nov. 14, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, President and Chief Executive Officer, will present at the 29t
Read more →AXGNAxoGen to Host Second Annual Analyst and Investor Day on November 20, 2017
ALACHUA, Fla., Nov. 07, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, today announced that it will host its Second Annual Analyst and Investor Day on Monday
Read more →AXGNAxoGen, Inc. Reports 2017 Third Quarter Financial Results Record Q3 Revenue of $16.0 million, representing 43% growth over prior year ALACHUA, FL –
AxoGen, Inc. Reports 2017 Third Quarter Financial Results Record Q3 Revenue of $16.0 million, representing 43% growth over prior year ALACHUA, FL November 1, 2017 AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the rep
Read more →AXGNAxoGen, Inc. Receives David J. Gury Company of the Year Award from BioFlorida
ALACHUA, Fla., Oct. 18, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has received the BioFlorida David J. Gury Company of the Year Award. The award, presented this wee
Read more →AXGNAxoGen, Inc. to Report Third Quarter 2017 Financial Results and Host Conference Call on November 1, 2017
ALACHUA, Fla., Oct. 17, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, today announced that it will report third quarter 2017 financial results on Wednesday,
Read more →AXGNAxoGen to Participate at 99th Annual American Association of Oral and Maxillofacial Surgeons Meeting
ALACHUA, Fla., Oct. 02, 2017 (GLOBE NEWSWIRE) -- AxoGen Corporation (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve damage, today announced it will participate in the 99th Annual Meeting of the American Association of
Read more →AXGNAxoGen to Participate at 72nd Annual American Society for Surgery of the Hand Meeting
ALACHUA, Fla., Aug. 24, 2017 (GLOBE NEWSWIRE) -- AxoGen Corporation (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced it will participate in the 72nd Annual Meeting of the American Society for S
Read more →AXGNAxoGen, Inc. Reports 2017 Second Quarter Financial Results Record Q2 Revenue of $15.2 million, representing 46% growth over prior year ALACHUA, FL –
AxoGen, Inc. Reports 2017 Second Quarter Financial Results Record Q2 Revenue of $15.2 million, representing 46% growth over prior year ALACHUA, FL August 2, 2017 AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripher
Read more →AXGNAxoGen, Inc. to Present at the Wedbush PacGrow Healthcare Conference
ALACHUA, Fla., July 31, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, President and Chief Executive Officer, will present at the Wed
Read more →AXGNAxoGen, Inc. Discloses Terms of Recent Equity Award
ALACHUA, Fla., July 20, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced the hiring of Jon Gingrich as its Chief Commercial Officer on July 17, 2017 on the terms
Read more →AXGNAxoGen, Inc. to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 2, 2017
ALACHUA, Fla., July 19, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2017 financial results on Wednesday, August 2,
Read more →AXGNAxoGen, Inc. Appoints Jon Gingrich Chief Commercial Officer ALACHUA, FL –
AxoGen, Inc. Appoints Jon Gingrich Chief Commercial Officer ALACHUA, FL July 17, 2017 -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jon S. Gingrich to the
Read more →AXGNAxoGen, Inc. to Present at the JMP Securities Life Sciences Conference
ALACHUA, Fla., June 07, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Peter J. Mariani, Chief Financial Officer, will present at the JMP Securities
Read more →AXGNAxoGen, Inc. Reports 2017 First Quarter Financial Results Record Q1 Revenue of $12.2 million, representing 51% growth over prior year ALACHUA, FL —
AxoGen, Inc. Reports 2017 First Quarter Financial Results Record Q1 Revenue of $12.2 million, representing 51% growth over prior year ALACHUA, FL May 4, 2017 AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral n
Read more →AXGNAxoGen, Inc. to Report First Quarter 2017 Financial Results and Host Conference Call on Thursday, May 4, 2017
ALACHUA, Fla., April 14, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2017 financial results on Thursday, May 4, 2017
Read more →AXGNAxoGen, Inc. Announces 2017 Annual Shareholders’ Meeting
Wednesday, May 24, 2017 at 4:00 p.m. Eastern Time Renaissance Orlando Airport Hotel, Orlando, FL ALACHUA, Fla., April 07, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries
Read more →AXGNAxoGen, Inc. to Present at the Oppenheimer 27th Annual Healthcare Conference
ALACHUA, Fla., March 07, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, President and Chief Executive Officer, will present at the Op
Read more →AXGN2016 Fourth Quarter and Full Year Financial Results
AxoGen, Inc. Reports 2016 Fourth Quarter and Full Year Financial Results Record Q4 Revenue of $11.4 million, representing 46% growth over prior year Record Full year 2016 Revenue of $41.1 million, representing 50% growth over prior year ALACHUA, FL February 22, 2017 AxoGen, I
Read more →AXGNAxoGen, Inc. Reports 2016 Fourth Quarter and Full Year Financial Results
Record Q4 Revenue of $11.4 million, representing 46% growth over prior year Record Full year 2016 Revenue of $41.1 million, representing 50% growth over prior year ALACHUA, Fla., Feb. 22, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and mar
Read more →AXGNAxoGen, Inc. to Report Fourth Quarter and 2016 Full Year Financial Results and Host Conference Call on Wednesday, February 22, 2017
ALACHUA, Fla., Feb. 08, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter and 2016 full year financial results on Wednesd
Read more →AXGNAxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2016 Revenue
Q4 Revenue will be at least $11.3 million, representing 45% growth over prior year 2016 Revenue will be at least $41.0 million, representing 50% growth over prior year ALACHUA, Fla., Jan. 09, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative sur
Read more →AXGNaxgn_Current Folio_Ex99_1_20170109 EXIHIBIT 99.1 AxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2016 Revenue Q4 Revenue will be at least $11.3 million, representing 45% growth over prior year 2016 Reven
AxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2016 Revenue Q4 Revenue will be at least $11.3 million, representing 45% growth over prior year 2016 Revenue will be at least $41.0 million, representing 50% growth over prior year ALACHUA, FL January 09, 2017 A
Read more →AXGNAxoGen Appoints Ivica Ducic Medical Director
ALACHUA, Fla., Jan. 05, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Ivica (Ivan) Ducic, M.D., Ph.D. as Medical Director of Clinical and Translational Scienc
Read more →AXGNAxoGen to Participate at AAHS ASPN ASRM Joint 2017 Annual Meeting
ALACHUA, Fla., Jan. 03, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced its participation at the joint 2017 Meeting of the American Association for Hand Surgery, American Society
Read more →AXGNAxoGen, Inc. announces Avance Nerve Graft Recipient to be honored on the Donate Life Tournament of Roses Parade Float
Marine Veteran’s Arm Saved from Amputation Following Severe Battle Injuries Promoting awareness of nerve injuries and tissue donation at the Tournament of Roses Parade ALACHUA, Fla., Dec. 14, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative sur
Read more →AXGNAxoGen, Inc. Announces Commercial Release and First Clinical Implant of Avive™ Soft Tissue Membrane
ALACHUA, Fla., Nov. 21, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced the commercial release and first clinical implant of Avive™ Soft Tissue Membrane. Avive™ Soft Tissue Membra
Read more →AXGNAxoGen, Inc. to Present at the 28th Annual Piper Jaffray Healthcare Conference
ALACHUA, Fla., Nov. 17, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray He
Read more →AXGNAxoGen, Inc. to Host Analyst and Investor Event on November 21, 2016
ALACHUA, Fla., Nov. 15, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that the company will host an Analyst and Investor Event on Monday, November 21st
Read more →AXGNAxoGen, Inc.
AxoGen, Inc. Reports Financial Results for Third Quarter 2016 Record revenues of $11.2 million, continued growth in accounts, and increased presence of nerve repair at key medical meetings ALACHUA, FL November 2, 2016 AxoGen, Inc. (NASDAQ: AXGN), a global leader in innovative s
Read more →AXGNAxoGen, Inc. Reports Financial Results for Third Quarter 2016
ALACHUA, Fla., Nov. 02, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced financial results for the third quarter ended September 30, 2016 and provided a business update. Third Qua
Read more →AXGNaxgn_Ex99_1 EXIBIT 99.1 AxoGen, Inc. Announces the Refinancing of its Debt Facility New Agreement Will Replace Existing $25 million Term Loan and Revenue Interest Royalty Agreement, and Reduce Annual Interest Costs by at
AxoGen, Inc. Announces the Refinancing of its Debt Facility New Agreement Will Replace Existing $25 million Term Loan and Revenue Interest Royalty Agreement, and Reduce Annual Interest Costs by at Least $1.5 Million ALACHUA, Fla., Oct. 26, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc.
Read more →AXGNAxoGen, Inc. Announces the Refinancing of its Debt Facility
ALACHUA, Fla., Oct. 26, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it has completed the refinancing of its existing debt agreement with a new fa
Read more →AXGNAxoGen, Inc. to Report Third Quarter Financial Results and Host Conference Call on Wednesday, November 2, 2016
ALACHUA, Fla., Oct. 19, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter financial results on Wednesday, November 2, 2016 after
Read more →AXGNAxoGen Announces Closing of Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
ALACHUA, Fla., Oct. 13, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced the closing of its previously announced underwritten public offering of 2,333,334 shares of its common stoc
Read more →AXGNAxoGen Announces Pricing of Public Offering of Common Stock
ALACHUA, Fla., Oct. 07, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced the pricing of an underwritten public offering of 2,333,334 shares of its common stock, offered at a price
Read more →AXGNAxoGen Announces Proposed Public Offering of Common Stock ALACHUA, FL.
AxoGen Announces Proposed Public Offering of Common Stock ALACHUA, FL., October 06, 2016 - - AxoGen, Inc. (NASDAQ: AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced that it intends to offer and sell, subject to market and othe
Read more →AXGNAxoGen, Inc. Appoints Amy Wendell to Board of Directors Former Covidien Senior Executive Brings More Than 30 Years of Experience to AxoGen Board ALACHUA, FL –
AxoGen, Inc. Appoints Amy Wendell to Board of Directors Former Covidien Senior Executive Brings More Than 30 Years of Experience to AxoGen Board ALACHUA, FL September 19, 2016 AxoGen, Inc. (NASDAQ: AXGN), a global leader in innovative surgical solutions for peripheral nerve inj
Read more →AXGNAxoGen to Participate at 71st Annual American Society for Surgery of the Hand Meeting
ALACHUA, Fla., Sept. 15, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced its participation at the 71st Annual American Society for Surgery of the Hand Meeting taking place in Aust
Read more →AXGNAxoGen, Inc. to Participate at the American Association of Oral and Maxillofacial Surgeons 98th Annual Meeting
ALACHUA, Fla., Sept. 12, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced its participation at the American Association of Oral and Maxillofacial Surgeons 98th Annual Meeting takin
Read more →AXGNAxoGen, Inc. to Present at Wedbush PacGrow Healthcare Conference 2016
ALACHUA, Fla., Aug. 11, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare C
Read more →AXGNAxoGen, Inc. Reports Financial Results for Second Quarter 2016 Second Quarter Revenues of $10.4M grew 62% over prior year ALACHUA, FL –
AxoGen, Inc. Reports Financial Results for Second Quarter 2016 Second Quarter Revenues of $10.4M grew 62% over prior year ALACHUA, FL August 3, 2016 AxoGen, Inc. (NASDAQ: AXGN), a global leader in innovative surgical solutions for peripheral nerve injuries, today announced fina
Read more →AXGNAxoGen, Inc. to Report Second Quarter Financial Results and Host Conference Call on Wednesday, August 3, 2016
ALACHUA, Fla., July 20, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter financial results on Wednesday, August 3, 2016 after t
Read more →AXGNAxoGen, Inc. Added to Russell 2000 Index
ALACHUA, Fla., June 27, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that the company has been added to the Russell 2000® Index, following the annual reconsti
Read more →AXGNAxoGen, Inc.’s Avance Nerve Graft Data to be Presented at 2016 Federation of European Societies for Surgery of the Hand International Congress
ALACHUA, Fla., June 21, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the acceptance of four presentations at the Congress of the Federation of European Societ
Read more →AXGNAxoGen to Present at JMP Securities Healthcare Conference 2016
ALACHUA, Fla., June 16, 2016 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Peter J. Mariani, Chief Financial Officer, will present at JMP Securities Healthcare
Read more →AXGNAxoGen , Inc. First Quarter Revenue Increases 64% Over Prior Year to $8.1 Million ALACHUA, FL –
AxoGen, Inc. First Quarter Revenue Increases 64% Over Prior Year to $8.1 Million ALACHUA, FL May 4, 2016 AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results for the first
Read more →AXGNAxoGen, Inc. to Report First Quarter Results
ALACHUA, Fla., April 20, 2016 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the first quarter ended March 31, 2016 on Wednesday, May 4, 2016 after the market
Read more →AXGNAxoGen, Inc. to Feature Nerve Repair Solutions at the American College of Oral and Maxillofacial Surgeons (ACOMS) Annual Scientific Conference and Exhibition
ALACHUA, Fla., April 8, 2016 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced its participation in the 2016 American College of Oral and Maxillofacial Surgeons
Read more →AXGNAxoGen, Inc. Launches AcroVal(TM) Neurosensory & Motor Testing System
ALACHUA, Fla., March 30, 2016 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the commercial release and first sale of AcroVal Neurosensory & Motor Testi
Read more →AXGNAxoGen, Inc. to Participate at the 28th Annual ROTH Growth Conference
ALACHUA, Fla., March 9, 2016 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that Karen Zaderej, President and Chief Executive Officer, is scheduled to present
Read more →AXGNAxoGen Appoints Peter J. Mariani Chief Financial Officer
ALACHUA, Fla., March 1, 2016 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Peter J. Mariani, as Chief Financial Officer, effective M
Read more →AXGNaxgn_Ex99_1 AxoGen Inc. Reports Record Revenue Results - Record Annual Revenue of $27.3 3 Million and Fourth Quarter Revenue of $7.8 1 Million - 2016 Outlook Provided ALACHUA, FL – February 29 , 201 6 – Axo
AxoGen Inc. Reports Record Revenue Results - Record Annual Revenue of $27.33 Million and Fourth Quarter Revenue of $7.81 Million - 2016 Outlook Provided ALACHUA, FL February 29, 2016 AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solution
Read more →AXGNAxoGen Inc. Reports Record Revenue Results
ALACHUA, Fla., Feb. 29, 2016 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported record 2015 revenue of $27.33 million and fourth quarter revenue of $7.81 mil
Read more →AXGNAxoGen, Inc. to Report Fourth Quarter and Full Year Results on February 29, 2016
ALACHUA, Fla., Feb. 10, 2016 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the fourth quarter and full year ended December 31, 2015 on Monday, February 29, 2
Read more →AXGNAxoGen, Inc. Avance(R) Nerve Graft Recipient to be Honored on Donate Life Rose Parade Float
ALACHUA, Fla., Dec. 28, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that Matthew Jayroe, one of the thousands of patients who have had injured nerves r
Read more →AXGNAxoGen Inc. Third Quarter Revenue Exceeds $8 Million - Revenue Increased 74.5 % ; Gross Profit Margin of 82.7 % ; AXGN Raises 2015 Guidance ALACHUA, FL – November 5 , 201 5 – AxoGen, Inc. (NASDAQ: AXGN), a
AxoGen Inc. Third Quarter Revenue Exceeds $8 Million - Revenue Increased 74.5%; Gross Profit Margin of 82.7%; AXGN Raises 2015 Guidance ALACHUA, FL November 5, 2015 AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral ne
Read more →AXGNAxoGen, Inc. to Report Third Quarter Results on November 5, 2015
ALACHUA, Fla., Oct. 16, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the third quarter and nine months ended September 30, 2015 on Thursday, November 5,
Read more →AXGNAxoGen, Inc. to Present at the Dawson James Securities Small Cap Growth Conference
ALACHUA, Fla., Oct. 8, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is scheduled to present at the Dawson James Securities 2015 Small Cap Growth Stock Conference
Read more →AXGNAxoGen, Inc. to Attend American Association of Oral and Maxillofacial Surgeons (AAOMS) 97th Annual Meeting
ALACHUA, Fla., Sept. 29, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced its participation in the 2015 American Association of Oral and Maxillofacial
Read more →AXGNAxoGen Inc.'s Avance(R) Nerve Graft Data Presented During Best Clinical Papers Session at the 70th Annual Meeting of the American Society for Surgery of the Hand
ALACHUA, Fla., Sept. 10, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the presentation of data on AxoGen's Avance Nerve Graft, including data from
Read more →AXGNEssex Woodlands Fund IX Acquires Significant Position in AxoGen, Inc. Investment of $17.5 Million Builds Company Balance Sheet ; Provides Resources to Drive Growth and Pursue Expansion Opportunities Guido J. Neels, Leadi
Essex Woodlands Fund IX Acquires Significant Position in AxoGen, Inc. Investment of $17.5 Million Builds Company Balance Sheet; Provides Resources to Drive Growth and Pursue Expansion Opportunities Guido J. Neels, Leading International Healthcare Executive, Joins Board of Direc
Read more →AXGNAxoGen, Inc. Expands Presence at the American Society for Surgery of the Hand (ASSH) 2015
ALACHUA, Fla., Aug. 24, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the expansion of their presence at this year's American Society for Surgery o
Read more →AXGNStrong Operatin g Momentum Leads to AxoGen Inc.'s First Ever $6 Million Quarter - Revenue Increased 52% to $6.4 Million ; Gross Profit Margin of 8 3.8 % - Solid Start to Second Half of 2015; Full Year Guidance Raised ALA
Strong Operating Momentum Leads to AxoGen Inc.'s First Ever $6 Million Quarter - Revenue Increased 52% to $6.4 Million; Gross Profit Margin of 83.8% - Solid Start to Second Half of 2015; Full Year Guidance Raised ALACHUA, FL August 6, 2015 AxoGen, Inc. (NASDAQ: AXGN), a leader
Read more →AXGNAxoGen, Inc. to Present at the Wedbush Healthcare Conference
ALACHUA, Fla., Aug. 3, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at
Read more →AXGNAxoGen, Inc. to Report Second Quarter Results on August 6, 2015
ALACHUA, Fla., July 15, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the second quarter and six months ended June 30, 2015 on Thursday, August 6, 2015 a
Read more →AXGNAxoGen, Inc. to Meet with Dr. Alejandro Toledo, Former President of Peru and Director of Global Center for Development and Democracy, During United Nations Meeting
ALACHUA, Fla., July 13, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Co-Founder and Vice President John P. Engels will meet with Dr. Alejandro Toledo, former Presid
Read more →AXGNAxoGen, Inc. to Be Featured on 'Living Better with Laura Smith' on ABC Radio
ALACHUA, Fla., June 26, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that ABC Radio's "Living Better with Laura Smith" will be featuring a special interview with Karen Z
Read more →AXGNAxoGen, Inc. Announces Enrollment of First Subject in Multicenter Comparative Study for Avance(R) Nerve Graft
ALACHUA, Fla., June 24, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ:AXGN), a leading medical technology company focused on restoring quality of life through nerve repair, announced today that the first subject has been enrolled in the "RECON Study" to support an Inv
Read more →AXGNAxoGen, Inc. Chief Marketing Officer Named CEO of Privately-held Life Sciences Company Plan in Place to Continue Driving Adoption of AxoGen Product Lines ALACHUA, FL
AxoGen, Inc. Chief Marketing Officer Named CEO of Privately-held Life Sciences Company Plan in Place to Continue Driving Adoption of AxoGen Product Lines ALACHUA, FL, June 19, 2015 AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on restoring quality of
Read more →AXGNAxoGen, Inc. To Host First International Surgeon Training Course and Announces Presentation of New Clinical Data at European Hand Meeting
ALACHUA, Fla., June 15, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on restoring quality of life through nerve repair, today announced full enrollment of its first OUS surgeon training course to be held immediatel
Read more →AXGNAxoGen, Inc. Announces Completion of a Pilot Clinical Study Assessing Cavernous Nerve Reconstruction with Avance(R) Nerve Graft Following Radical Prostatectomy
ALACHUA, Fla., June 9, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced results from a pilot clinical study of cavernous nerve reconstruction during radical prostatectom
Read more →AXGNAxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter
ALACHUA, Fla., May 5, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the $1.6 billion peripheral nerve repair market, reported record revenue of $4.95 million for the first quarter ended March 31, 2015 compared to
Read more →AXGNAxoGen, Inc. Announces Clearance from FDA to Proceed with New Multicenter Comparative Study for Avance(R) Nerve Graft
ALACHUA, Fla., May 4, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to the $1.6 billion peripheral nerve repair market, announced today that the U.S. Food and Drug Administration (FDA) has given AxoGen clearance t
Read more →AXGNAxoGen, Inc. Announces 2015 Annual Shareholders' Meeting
ALACHUA, Fla., April 27, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that it will hold its Annual Shareholders' Meeting on Thursday, May 28, 2015. The Meeting will tak
Read more →AXGNAxoGen, Inc. to Report First Quarter Financial Results on May 5, 2015
ALACHUA, Fla., April 21, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the first quarter of 2015 on Tuesday, May 5, 2015 following the close of the mark
Read more →AXGNAxoGen, Inc. to Participate in American Academy of Orthopedic Surgeons (AAOS) 2015 Annual Meeting
ALACHUA, Fla., March 23, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced that it will be highlighting its products at the American Academy of Orthopedic Surgeons (AAOS)
Read more →AXGNAxoGen, Inc. CEO Karen Zaderej to Discuss AxoGen's Growth, Nerve Injuries and New Options for Nerve Repair on "The Big Biz Show"
ALACHUA, Fla., March 19, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Chief Executive Officer Karen Zaderej will be interviewed on BizTalkRadio's "The Big Biz Show"
Read more →AXGNAxoGen, Inc. to Present at Canaccord Genuity's Musculoskeletal Conference
ALACHUA, Fla., March 16, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, is scheduled to present at the Annual Canaccord Genuity Musculoskeletal Conference on Tuesday, March 24,
Read more →AXGNAxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter AXGN fourth quarter revenue reaches $4.79 million and full year 2014 revenue increases 54% to $16.8 million. Company Introduces full year 2015 revenue g
AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter AXGN fourth quarter revenue reaches $4.79 million and full year 2014 revenue increases 54% to $16.8 million. Company Introduces full year 2015 revenue guidance to exceed $24 million ALACHUA, FL March 5, 2015 A
Read more →AXGNAxoGen, Inc. to Report Fourth Quarter and Full Year Financial Results on March 5, 2015
ALACHUA, Fla., Feb. 26, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the fourth quarter and full year ended December 31, 2014 on Thursday, March 5, 2015
Read more →AXGNAxoGen, Inc. Announces Presentation of Additional Clinical Data For Avance(R) Nerve Graft
ALACHUA, Fla., Feb. 25, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, today announced additional clinical data from the RANGER Stu
Read more →AXGNAxoGen, Inc. Prices Public Offering of Common Stock Nerve repair company prices public offering of common stock ALACHUA, FL
AxoGen, Inc. Prices Public Offering of Common Stock Nerve repair company prices public offering of common stock ALACHUA, FL, February 05, 2015 AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair inj
Read more →AXGNAxoGen, Inc. Prices Public Offering of Common Stock
ALACHUA, Fla., Feb. 5, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, has announced the pricing of an underwritten public offering o
Read more →AXGNAxoGen, Inc. Announces Preliminary Fourth Quarter and Full Year Revenue Nerve repair company expects to report 54% growth over previous year. ALACHUA, FL
AxoGen, Inc. Announces Preliminary Fourth Quarter and Full Year Revenue Nerve repair company expects to report 54% growth over previous year. ALACHUA, FL February 4, 2015 AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company with a unique and innovative portfolio of
Read more →AXGNAxoGen, Inc. to Host Surgeon Education Event at AAHS ASPN ASRM Joint 2015 Annual Meeting
ALACHUA, Fla., Jan. 22, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced that it will sponsor an educational forum for surgeons at the Joint Annual Meetings of the Americ
Read more →AXGNAxoGen, Inc. CMO Jill Schiaparelli and Oral Maxillofacial Surgeon Dr. Shahrokh Bagheri to Discuss Nerve Injury and Repair Options Live on iHeart Business Talk Radio HealthTech Talk Live -- January 10, 2015
ALACHUA, FL--(Marketwired - Jan 9, 2015) - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Chief Marketing Officer Jill Schiaparelli will be interviewed live on iHeart Radio's debut episode of HealthTech
Read more →AXGNAxoGen, Inc. Promotes Jill Schiaparelli to Chief Marketing Officer
ALACHUA, Fla., Jan. 6, 2015 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a growing medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, announced that Jill Schiaparelli has been promoted to the rol
Read more →AXGNAxoGen, Inc. Avance(R) Nerve Graft Recipient to be honored on Donate Life Rose Parade Float on New Year's Day
ALACHUA, Fla., Dec. 23, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, announced that Shirley Pincus, one of the thousands of p
Read more →AXGNAxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on December 2
ALACHUA, Fla., Dec. 2, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Micha
Read more →AXGNAxoGen, Inc. Reports 58% Third Quarter Revenue Growth Quarterly Record Revenue of $4.67 Million. New Financing Agreement Substantially Lowers Future Yearly Debt Payments ALACHUA, FL
AxoGen, Inc. Reports 58% Third Quarter Revenue Growth Quarterly Record Revenue of $4.67 Million. New Financing Agreement Substantially Lowers Future Yearly Debt Payments ALACHUA, FL November 13, 2014 AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on
Read more →AXGNAxoGen, Inc. Signs Agreement with Oberland Capital
ALACHUA, Fla., Nov. 13, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, has entered into a $28.55 million financing agreement with Three Peaks Capital S.a.r.l., an indirect wholl
Read more →AXGNAxoGen, Inc. to Report Third Quarter Financial Results on November 13, 2014
ALACHUA, Fla., Nov. 6, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the third quarter ended September 30, 2014 on Thursday, November 13, 2014 after the
Read more →AXGNAxoGen, Inc. Announces Presentation of Clinical Data for Avance(R) Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting
ALACHUA, Fla., Sept. 30, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced the presentation of clinical data for Avance Nerve Graft during the American Society for Surger
Read more →AXGNAxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting
ALACHUA, Fla., Sept. 16, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced that it will sponsor an educational forum at the American Society for Surgery of the Hand (ASSH)
Read more →AXGNAxoGen, Inc. to Host Surgeon Panel on Nerve Repair at American Association of Oral and Maxillofacial Surgeons Annual Meeting 2014
ALACHUA, Fla., Sept. 9, 2014 (GLOBE NEWSWIRE) -- via PRWEB - A xoGen, Inc. (Nasdaq:AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced that it will sponsor a panel discussion at the 96th Annual Meeting of the Ame
Read more →AXGNAxoGen, Inc. Announces Changes to Board of Directors
ALACHUA, Fla., Aug. 25, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported today that John McLaughlin, President and Chief Executive Officer of PDL BioPharma, Inc. has resi
Read more →AXGNAxoGen, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
ALACHUA, Fla., Aug. 5, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on T
Read more →AXGNAxoGen, Inc. Reports 47% Second Quarter Revenue Growth Quarterly Record Revenue of $4.2 Million; Gross Margin expands to 79%. Conference Call Today at 4:30 pm
AxoGen, Inc. Reports 47% Second Quarter Revenue Growth Quarterly Record Revenue of $4.2 Million; Gross Margin expands to 79%. Conference Call Today at 4:30 pm ET ALACHUA, FL August 4, 2014 AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the periphe
Read more →AXGNAxoGen, Inc. to Report Second Quarter Financial Results on August 4, 2014
ALACHUA, Fla., July 15, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close o
Read more →AXGNAxoGen, Inc. To Present Nerve Repair Data at 2014 Federation of European Societies for Surgery of the Hand (FESSH) International Congress
ALACHUA, Fla., June 18, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, today announced the acceptance of two clinical presentations on the use of Avance Nerve Graft and a scient
Read more →AXGNAxoGen, Inc. on Preliminary List of Additions to Russell Microcap(R) Index
ALACHUA, Fla., June 16, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, announced today that it was included on a preliminary list of additions to the Russell Micr
Read more →AXGNAxoGen, Inc. to Present at JMP Securities Healthcare Conference
ALACHUA, Fla., June 9, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, is scheduled to present at the 9th Annual JMP Securities Healthcare Conference on Tuesday, J
Read more →AXGNAxoGen, Inc. Receives Department of Defense Funding for Next Generation Peripheral Nerve Repair Research
ALACHUA, Fla., June 4, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, announced today that it would share in the award of two Department of Defense Grants totaling approximately $1.9 mi
Read more →AXGNAxoGen, Inc. Appoints Lee Robert Johnston, Jr. Chief Financial Officer
ALACHUA, Fla., May 12, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, announced the appointment of Lee Robert Johnston, Jr, as Chief Financial Officer, effective
Read more →AXGNAxoGen, Inc. Reports 46% First Quarter Revenue Growth Quarterly Revenues Exceeds $3 Million for First Time in Company History Gross margin expands to 77.7% Conference call today at 4:30 pm
AxoGen, Inc. Reports 46% First Quarter Revenue Growth Quarterly Revenues Exceeds $3 Million for First Time in Company History Gross margin expands to 77.7% Conference call today at 4:30 pm ET ALACHUA, FL April 30, 2014 AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology
Read more →AXGNAxoGen, Inc. Reports 46% Fourth Quarter and 42% Full Year 2013 Revenue Growth Company Reports Continued Progress in Nerve Repair Market Conference Call Today at 4:30 p.m.
AxoGen, Inc. Reports 46% Fourth Quarter and 42% Full Year 2013 Revenue Growth Company Reports Continued Progress in Nerve Repair Market Conference Call Today at 4:30 p.m. ET ALACHUA, FL March 6, 2014 AxoGen, Inc. (NASDAQ: AXGN), the emerging leader of the $1.6 billion U.S. per
Read more →AXGNAxoGen CEO Karen Zaderej Interview on Clear Channel Business Talk Radio DFW1190AM by Michael Yorba
ALACHUA, FL--(Marketwired - Dec 13, 2013) - AxoGen, Inc. (NASDAQ: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced CEO Karen Zaderej will be interviewed live today at 3:45pm EST on Clear Channel's business tal
Read more →Competitive Position
How AXGN ranks across every disease it competes inCompetitive Position is a premium feature
See how AXGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial